Sponsor: University of Oxford
EudraCT number: 2009-016459-23
Funded by: GlaxoSmithKline
Endorsed by: Cancer Research UK
Phase II single arm multi-centre NCRI feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome. The study has been added to the NIHR CRN Portfolio database, study ID: 9476.
In the CHOP-OR trial, we are asking the following two questions:
- Does the combination of chemotherapy and Ofatumumab improve outcomes compared to chemotherapy on its own?
- Are there any rare side effects of Ofatumumab in combination with chemotherapy that we do not know about?
CLOSED to recruitment 19 Dec 2014
Target recruitment: 41 patients (35 evaluable)
Final recruitment: 43 patients
Total number of sites: 10
List of sites:
- Addenbrooke’s Hospital, Cambridge
- The Christie, Manchester
- Churchill Hospital, Oxford
- City Hospital Campus, Nottingham
- Kings College, London
- Queen Elizabeth, Birmingham
- Royal Bournemouth Hospital
- Royal Liverpool University Hospital
- St Bartholomew’s Hospital, London
- St James’s University Hospital, Leeds
Information for patients & their families about the CHOP-OR trial is available from the Cancer Research UK CancerHelp website: CancerHelp CHOP-OR Trial
If you are interested in participating in this trial please discuss this with your Doctor and if necessary ask to be referred to one of the hospitals in the list of active sites above.
- Signed written informed consent prior to performing any study-specific procedures.
- Patients with B-CLL and newly diagnosed not previously treated and biopsy proven DLBCL Richter’s transformation
- ECOG Performance Status of 0, 1, 2 or 3.
- Age 18 years and over.
- Computerised tomography (CT) scan performed within 8 weeks prior to starting treatment.
- CHOP or CHOP-like anthracycline containing treatment for DLBCL within 6 months prior to registration. (please note that pre-treatment with Prednisolone up to 2mg/kg prior to entering the study is allowed.)
- Known CNS involvement of B-CLL
- Any other malignancy that requires active treatment with the exception of basal cell carcinoma and non-invasive squamous cell carcinoma
- Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis.
- Subjects meeting any of the following criteria must not be enrolled in the study: Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. (In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded). Consent will be sought prior to any test being performed.
- Clinically significant cardiac disease including unstable angina, uncontrolled congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities
- Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease
- History of significant cerebrovascular disease in last 6 months
- Known HIV positive
- Known or suspected hypersensitivity to components of investigational product
- Patients who have received treatment with any non-marketed drug substance or experimental therapy within 4 weeks prior to Visit 2 (start of treatment, cycle 1 day 1)
- Current participation in any other interventional clinical study
- Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
- Breast feeding women or women with a positive pregnancy test at screening.
- Women of childbearing potential not willing to use adequate contraception during study and for two months after last dose of ofatumumab. Adequate contraception is defined as abstinence, hormonal birth control or intrauterine devices.
- Evaluate overall response rate (ORR) to CHOP-O according to the Revised Response Criteria for Malignant Lymphoma (Cheson criteria).
- Feasability of recruitment.
- Progression free survival (PFS).
- Overall Survival (OS).
- The clinical benefit and changes in patient reported outcome measures (PRO).
- Safety and tolerability.
Data submission for this trial is via electronic submission of data in OpenClinica.
Results can be viewed at the following link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016459-23/results